

North Central Cancer Treatment Group

N0177: Pilot and Phase II Trial of OSI-774 and Radiation in Glioblastoma Multiforme Patients

Status Change – April 21, 2004

NOTICE OF STATUS CHANGE

Study 1 is reopened to patient accrual at dose level 2A (150 mg OSI-774) effective immediately **Wednesday, April 21, 2004** for the accrual of one additional patient.

Please retain this notice with the protocol.